teaser
Pfizer’s late-stage drugs pipeline has suffered another rupture with the news that the firm has terminated trials of an experimental lung cancer treatment.
The New York-based drugs giant said it has discontinued a development programme in advanced nonsmall-cell lung cancer for PF-3512676 in combination with cytotoxic chemotherapy. This includes two phase III and two phase III trials of the drug, previously called ProMune
